SCHEMBL2029201

SCHEMBL2029201

Oc1ccccc1-c1nnc2c3ccccc3c(Cl)nn12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
TP53 P04637 2/20 0.45
MAPT P10636 2/20 0.45
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 1/20 0.43
TSHR P16473 1/20 0.43
RAB9A P51151 1/20 0.43
HTT P42858 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
APAF1 O14727 1/20 0.40
HPGD P15428 1/20 0.40
RECQL P46063 1/20 0.40
PDE2A O00408 2/20 0.40
PDE10A Q9Y233 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2830794 0.85 RXFP1 (0.62) RXFP1L3MBTL1TP53MAPTPOLB
SCHEMBL497344 0.84 RXFP1 (0.65) RXFP1L3MBTL1TP53MAPTPOLB
SCHEMBL497264 0.82 RXFP1 (0.59) RXFP1L3MBTL1TP53MAPTPOLB
SCHEMBL496713 0.82 RXFP1 (0.59) RXFP1L3MBTL1TP53MAPTPOLB
SCHEMBL496580 0.79 RXFP1 (0.58) RXFP1L3MBTL1TP53MAPTPOLB
SCHEMBL496605 0.79 RXFP1 (0.55) RXFP1L3MBTL1TP53MAPTPOLB
SCHEMBL497285 0.78 NPC1 (0.69) RXFP1L3MBTL1MAPTSMN1; SMN2NPC1
SCHEMBL31146696 0.74 RXFP1 (1.00) RXFP1L3MBTL1SMN1; SMN2NPC1TSHR
SCHEMBL5524673 0.74 RXFP1 (1.00) RXFP1L3MBTL1SMN1; SMN2NPC1TSHR
SCHEMBL14832794 0.74 RXFP1 (0.69) RXFP1L3MBTL1MAPTSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1874775-B1 TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS NYCOMED GMBH (DE) 2012-10-10 EP disclosed
US-20110136803-A1 Triazolophthalazines NYCOMED GMBH (DE) 2011-06-09 US disclosed
US-7671050-B2 Triazolophthalazines NYCOMED GMBH (DE) 2010-03-02 US disclosed
US-20080280907-A1 Triazolophthalazines AALTANA PHARMA AG (DE) 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280907-A1 Triazolophthalazines PDE2A, PDE3A, PDE12 RXFP1 292/4885L3MBTL1 4111/4885TP53 4666/4885
US-20110136803-A1 Triazolophthalazines PDE2A, PDE3A, PDE12 RXFP1 292/4885L3MBTL1 4111/4885TP53 4666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.